Sponsors (4)
Introduced July 15, 2025 by James E. Banks · Last progress July 15, 2025
The bill secures predictable, dedicated funding and clearer administrative procedures for FDA oversight of OTC monograph drugs—helping review, standardization, and planning—but does so by imposing earlier or higher fees and administrative complexity that risk passing costs to consumers, straining small businesses, reducing budget flexibility, and potentially weakening safeguards if consensus standards or sunsets are mishandled.
Patients (including those with chronic conditions) and hospitals/health systems will see more reliable and sustained FDA review and safety oversight of OTC monograph drugs because the bill dedicates and schedules user-fee funding for those activities.
Manufacturers and pharmacies will get clearer regulatory expectations because the FDA can recognize external consensus standards, which can speed quality harmonization and reduce compliance uncertainty.
Small businesses, regulated facilities, and FDA will benefit from clearer, more predictable administrative rules—fee periods, due dates, 60‑day advance publication of fees, and annual reporting—that improve budgeting and planning.
Manufacturers, hospitals, and ultimately consumers and taxpayers will face higher or earlier user fees (including specified one‑time revenue additions and potential one‑time increases), which can raise product prices or health‑system costs.
Small manufacturers and other regulated facilities will face short‑term cash‑flow strain from changed timing and installment structures and from costs of one‑time fee adjustments.
Patients and public health risk reduced safeguards if FDA relies on weak external consensus standards, which could lower regulatory scrutiny or permit less rigorous tests.
Based on analysis of 8 sections of legislative text.
Revises how OTC monograph facility user fees are calculated and timed, updates a definition for testing-procedure changes tied to consensus standards, adjusts annual reporting timing, and sets sunsets and effective dates.
Makes changes to how FDA calculates, schedules, and reports over-the-counter (OTC) monograph drug facility user fees, clarifies what testing-procedure changes count as fee-related activities, and sets an effective date and statutory sunsets for those authorities. It sets special revenue components for facility fees for FY2026–FY2030 (including specified one-time dollar amounts), revises the periods and due dates used to assess fees, and requires annual reporting within 120 days after each fiscal year. Also preserves the pre-amendment fee rules for assessing fees before FY2026, sets the Act to take effect October 1, 2025 (or later if enacted after that date) while requiring fees be assessed beginning October 1, 2025, and terminates the amended user-fee provisions in 2030–2031 unless extended again.